Market Likes Telaprevir For Twice-daily Dosing
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive assessment follows market uncertainty as Vertex issues incorrect data, then makes correction.
You may also be interested in...
Potential HCV Blockbuster, Strong Fundraising Place Vertex In Enviable Position
Well-financed biotech looks set to advance telaprevir and CF candidate despite tough financial markets.
Potential HCV Blockbuster, Strong Fundraising Place Vertex In Enviable Position
Well-financed biotech looks set to advance telaprevir and CF candidate despite tough financial markets.
Roche Advances In HCV Protease Inhibitor Contest
Swiss pharma will move ITMN-191 into Phase II studies, triggering a $15 million milestone to InterMune.